ArticleFrontiers in medicine2026
A patient with CKD complicated by secondary hyperparathyroidism and parathyroid carcinoma: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parathyroid carcinoma (PC) is a rare malignancy, representing approximately 0.005% of all malignant tumors. Currently, its etiopathogenesis, diagnostic criteria, and optimal management strategies remain poorly defined. Furthermore, the occurrence of PC in the context of secondary hyperparathyroidism (SHPT) is an infrequent clinical event. This report details a case of PC arising in a patient with chronic kidney disease (CKD) and SHPT. Case presentation: A 53-year-old male with severe renal failure was admitted for clinical evaluation. During the course of hospitalization, SHPT and PC were diagnosed based on clinical, biochemical, and imaging evaluations. Intraoperative pathological assessment confirmed the malignancy, necessitating radical resection with regional lymph node dissection. The patient has achieved a long term disease free survival exceeding 8 years after surgery. Conclusion: The diagnosis of PC remains clinically challenging due to its rarity and the significant overlap in biochemical and imaging features with benign parathyroid lesions. This diagnostic challenge is further intensified in patients with severe renal insufficiency, as characteristic clinical indicators are often masked by comorbid secondary hyperparathyroidism. This report illustrates the diagnostic process and successful long-term management of PC in this challenging context, providing a clinical reference for the standardized treatment of this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.